CytoDyn to Present at Wall Street Reporter’s NEXT SUPERSTOCK Livestream Event on Its Monoclonal Anti-CCR5 Antibody (Leronlimab) for COVID-19, and Also for HIV, Cancer, & Graft Versus Host Disease; Wednesday, May 13, 2020, at 12:30 pm EDT / 9:30 am PDT

On May 11, 2020, CytoDyn Inc. (OTC.QB: CYDY), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced that Jacob Lalezari, MD, CEO of Quest Clinical Research: Bruce Patterson, MD, Chief Executive Officer and Founder of IncellDx, a diagnostics company, and an advisor to CytoDyn; and Nader Pourhassan, PhD, President and Chief Executive Officer of CytoDyn, will provide a comprehensive business update. The Wall Street Reporter’s event is scheduled for Wednesday, May 13, 2020 at 12:30 pm ET / 9:30 am PT. The presentation will be approximately 15 minutes, followed by a Q&A session of approximately 45 minutes. You may register for the event at the following link ( Interested participants are encouraged to log in early prior to the start of the event, as the online event has a capacity of 3,000 participants. Please note that there will be no telephone access; this is a webcast-only event. The livestream presentation will be archived for 30 days. For anyone unable to attend, a video will be posted on CytoDyn’s website approximately 24 hours after the presentation. The conference sponsor provides corporate visibility services to CytoDyn for a fee. CytoDyn is currently enrolling patients in two clinical trials for COVID-19, a Phase 2 randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and a Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country. SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious.
Login Or Register To Read Full Story